Monoclonal antibodies in cancer therapy
A review of the clinical trials of antibody based cancer therapies reveals that this approach can, in rare cases, induce complete remissions in individual patients with cancer. Since these trials have usually involved patients with large tumor masses, tumor cell inaccessibility is probably a major r...
Gespeichert in:
| Veröffentlicht in: | Current opinion in immunology 1993-10, Vol.5 (5), p.732-739 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 739 |
|---|---|
| container_issue | 5 |
| container_start_page | 732 |
| container_title | Current opinion in immunology |
| container_volume | 5 |
| creator | Riethmüller, Gert Schneider-Gädicke, Elena Johnson, Judith P. |
| description | A review of the clinical trials of antibody based cancer therapies reveals that this approach can, in rare cases, induce complete remissions in individual patients with cancer. Since these trials have usually involved patients with large tumor masses, tumor cell inaccessibility is probably a major reason for the prevailing failures. Minimal residual disease, the stage when tumor cells are few and dispersed, should therefore be a more promising target for therapeutic antibodies. This hypothesis is supported by a prospective randomized trial on patients with resected Dukes C colorectal carcinoma that resulted in increased survival and prolonged recurrence-free intervals. Thus, in addition to strategies designed to produce more effective, human-derived reagents, efforts need to be concentrated on directing passive antibody therapy towards the appropriate target. |
| doi_str_mv | 10.1016/0952-7915(93)90129-G |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_16697949</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>095279159390129G</els_id><sourcerecordid>16697949</sourcerecordid><originalsourceid>FETCH-LOGICAL-c388t-8e19e1076de576e0731d56d8f02348b47b36a9b6863a24c5dd40a865b32948b83</originalsourceid><addsrcrecordid>eNp9kMtKAzEUhoMotVbfQGFWXhajyWRy2whStAoVN7oOmeQUI9NJTWaEvr2pLV26Oov_cvg_hM4JviWY8DusWFUKRdi1ojcKk0qVswM0JlKoElNRHaLx3nKMTlL6whgzRvEIjWRVY0HZGF29hi7YNnSmLUzX-yY4D6nwXWFNZyEW_SdEs1qfoqOFaROc7e4EfTw9vk-fy_nb7GX6MC8tlbIvJRAFBAvugAkO-QdxjDu5wBWtZVOLhnKjGi45NVVtmXM1NpKzhlYq65JO0OW2dxXD9wCp10ufLLSt6SAMSRPOlVC1ysZ6a7QxpBRhoVfRL01ca4L1ho_ejNeb8VpR_cdHz3LsYtc_NEtw-9AOSNbvtzrkkT8eok7WQybhfATbaxf8_w9-AUWZcnU</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>16697949</pqid></control><display><type>article</type><title>Monoclonal antibodies in cancer therapy</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Riethmüller, Gert ; Schneider-Gädicke, Elena ; Johnson, Judith P.</creator><creatorcontrib>Riethmüller, Gert ; Schneider-Gädicke, Elena ; Johnson, Judith P.</creatorcontrib><description>A review of the clinical trials of antibody based cancer therapies reveals that this approach can, in rare cases, induce complete remissions in individual patients with cancer. Since these trials have usually involved patients with large tumor masses, tumor cell inaccessibility is probably a major reason for the prevailing failures. Minimal residual disease, the stage when tumor cells are few and dispersed, should therefore be a more promising target for therapeutic antibodies. This hypothesis is supported by a prospective randomized trial on patients with resected Dukes C colorectal carcinoma that resulted in increased survival and prolonged recurrence-free intervals. Thus, in addition to strategies designed to produce more effective, human-derived reagents, efforts need to be concentrated on directing passive antibody therapy towards the appropriate target.</description><identifier>ISSN: 0952-7915</identifier><identifier>EISSN: 1879-0372</identifier><identifier>DOI: 10.1016/0952-7915(93)90129-G</identifier><identifier>PMID: 8240735</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject>Antibodies, Monoclonal - therapeutic use ; Antibodies, Neoplasm - immunology ; Antigens, Neoplasm - immunology ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Combined Modality Therapy ; Humans ; Immunization, Passive ; Immunotoxins - therapeutic use ; Neoplasms - immunology ; Neoplasms - therapy ; Vaccination</subject><ispartof>Current opinion in immunology, 1993-10, Vol.5 (5), p.732-739</ispartof><rights>1993</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c388t-8e19e1076de576e0731d56d8f02348b47b36a9b6863a24c5dd40a865b32948b83</citedby><cites>FETCH-LOGICAL-c388t-8e19e1076de576e0731d56d8f02348b47b36a9b6863a24c5dd40a865b32948b83</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/0952-7915(93)90129-G$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,777,781,3538,27906,27907,45977</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/8240735$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Riethmüller, Gert</creatorcontrib><creatorcontrib>Schneider-Gädicke, Elena</creatorcontrib><creatorcontrib>Johnson, Judith P.</creatorcontrib><title>Monoclonal antibodies in cancer therapy</title><title>Current opinion in immunology</title><addtitle>Curr Opin Immunol</addtitle><description>A review of the clinical trials of antibody based cancer therapies reveals that this approach can, in rare cases, induce complete remissions in individual patients with cancer. Since these trials have usually involved patients with large tumor masses, tumor cell inaccessibility is probably a major reason for the prevailing failures. Minimal residual disease, the stage when tumor cells are few and dispersed, should therefore be a more promising target for therapeutic antibodies. This hypothesis is supported by a prospective randomized trial on patients with resected Dukes C colorectal carcinoma that resulted in increased survival and prolonged recurrence-free intervals. Thus, in addition to strategies designed to produce more effective, human-derived reagents, efforts need to be concentrated on directing passive antibody therapy towards the appropriate target.</description><subject>Antibodies, Monoclonal - therapeutic use</subject><subject>Antibodies, Neoplasm - immunology</subject><subject>Antigens, Neoplasm - immunology</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Combined Modality Therapy</subject><subject>Humans</subject><subject>Immunization, Passive</subject><subject>Immunotoxins - therapeutic use</subject><subject>Neoplasms - immunology</subject><subject>Neoplasms - therapy</subject><subject>Vaccination</subject><issn>0952-7915</issn><issn>1879-0372</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1993</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kMtKAzEUhoMotVbfQGFWXhajyWRy2whStAoVN7oOmeQUI9NJTWaEvr2pLV26Oov_cvg_hM4JviWY8DusWFUKRdi1ojcKk0qVswM0JlKoElNRHaLx3nKMTlL6whgzRvEIjWRVY0HZGF29hi7YNnSmLUzX-yY4D6nwXWFNZyEW_SdEs1qfoqOFaROc7e4EfTw9vk-fy_nb7GX6MC8tlbIvJRAFBAvugAkO-QdxjDu5wBWtZVOLhnKjGi45NVVtmXM1NpKzhlYq65JO0OW2dxXD9wCp10ufLLSt6SAMSRPOlVC1ysZ6a7QxpBRhoVfRL01ca4L1ho_ejNeb8VpR_cdHz3LsYtc_NEtw-9AOSNbvtzrkkT8eok7WQybhfATbaxf8_w9-AUWZcnU</recordid><startdate>19931001</startdate><enddate>19931001</enddate><creator>Riethmüller, Gert</creator><creator>Schneider-Gädicke, Elena</creator><creator>Johnson, Judith P.</creator><general>Elsevier Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>H94</scope></search><sort><creationdate>19931001</creationdate><title>Monoclonal antibodies in cancer therapy</title><author>Riethmüller, Gert ; Schneider-Gädicke, Elena ; Johnson, Judith P.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c388t-8e19e1076de576e0731d56d8f02348b47b36a9b6863a24c5dd40a865b32948b83</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1993</creationdate><topic>Antibodies, Monoclonal - therapeutic use</topic><topic>Antibodies, Neoplasm - immunology</topic><topic>Antigens, Neoplasm - immunology</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Combined Modality Therapy</topic><topic>Humans</topic><topic>Immunization, Passive</topic><topic>Immunotoxins - therapeutic use</topic><topic>Neoplasms - immunology</topic><topic>Neoplasms - therapy</topic><topic>Vaccination</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Riethmüller, Gert</creatorcontrib><creatorcontrib>Schneider-Gädicke, Elena</creatorcontrib><creatorcontrib>Johnson, Judith P.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><jtitle>Current opinion in immunology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Riethmüller, Gert</au><au>Schneider-Gädicke, Elena</au><au>Johnson, Judith P.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Monoclonal antibodies in cancer therapy</atitle><jtitle>Current opinion in immunology</jtitle><addtitle>Curr Opin Immunol</addtitle><date>1993-10-01</date><risdate>1993</risdate><volume>5</volume><issue>5</issue><spage>732</spage><epage>739</epage><pages>732-739</pages><issn>0952-7915</issn><eissn>1879-0372</eissn><abstract>A review of the clinical trials of antibody based cancer therapies reveals that this approach can, in rare cases, induce complete remissions in individual patients with cancer. Since these trials have usually involved patients with large tumor masses, tumor cell inaccessibility is probably a major reason for the prevailing failures. Minimal residual disease, the stage when tumor cells are few and dispersed, should therefore be a more promising target for therapeutic antibodies. This hypothesis is supported by a prospective randomized trial on patients with resected Dukes C colorectal carcinoma that resulted in increased survival and prolonged recurrence-free intervals. Thus, in addition to strategies designed to produce more effective, human-derived reagents, efforts need to be concentrated on directing passive antibody therapy towards the appropriate target.</abstract><cop>England</cop><pub>Elsevier Ltd</pub><pmid>8240735</pmid><doi>10.1016/0952-7915(93)90129-G</doi><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0952-7915 |
| ispartof | Current opinion in immunology, 1993-10, Vol.5 (5), p.732-739 |
| issn | 0952-7915 1879-0372 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_16697949 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Antibodies, Monoclonal - therapeutic use Antibodies, Neoplasm - immunology Antigens, Neoplasm - immunology Antineoplastic Combined Chemotherapy Protocols - therapeutic use Combined Modality Therapy Humans Immunization, Passive Immunotoxins - therapeutic use Neoplasms - immunology Neoplasms - therapy Vaccination |
| title | Monoclonal antibodies in cancer therapy |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-17T08%3A59%3A55IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Monoclonal%20antibodies%20in%20cancer%20therapy&rft.jtitle=Current%20opinion%20in%20immunology&rft.au=Riethm%C3%BCller,%20Gert&rft.date=1993-10-01&rft.volume=5&rft.issue=5&rft.spage=732&rft.epage=739&rft.pages=732-739&rft.issn=0952-7915&rft.eissn=1879-0372&rft_id=info:doi/10.1016/0952-7915(93)90129-G&rft_dat=%3Cproquest_cross%3E16697949%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=16697949&rft_id=info:pmid/8240735&rft_els_id=095279159390129G&rfr_iscdi=true |